Review



vx 984 m9831  (Vertex Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Vertex Pharmaceuticals vx 984 m9831
    Synthesis of <t>VX-984:</t> A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.
    Vx 984 M9831, supplied by Vertex Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vx+984+m9831/984+m9831+vx/pmc13244300-165-0-12
    Average 86 stars, based on 1 article reviews
    vx 984 m9831 - by Bioz Stars, 2026-10
    86/100 stars

    Images

    1) Product Images from "Targeting DNA-PK: medicinal chemistry insights into small-molecule inhibitor discovery and optimisation"

    Article Title: Targeting DNA-PK: medicinal chemistry insights into small-molecule inhibitor discovery and optimisation

    Journal: RSC Medicinal Chemistry

    doi: 10.1039/d6md00119j

    Synthesis of VX-984: A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.
    Figure Legend Snippet: Synthesis of VX-984: A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.

    Techniques Used: Reflux



    Similar Products

    vx 984 m9831  (Vertex Pharmaceuticals)
    86
    Vertex Pharmaceuticals vx 984 m9831
    Synthesis of <t>VX-984:</t> A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.
    Vx 984 M9831, supplied by Vertex Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vx+984+m9831/984+m9831+vx/pmc13244300-165-0-12
    Average 86 stars, based on 1 article reviews
    vx 984 m9831 - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    co-crystal form of 48b vx-984 m9831  (Vertex Pharmaceuticals)
    90
    Vertex Pharmaceuticals co-crystal form of 48b vx-984 m9831
    Synthesis of <t>VX-984:</t> A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.
    Co Crystal Form Of 48b Vx 984 M9831, supplied by Vertex Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vx+984+m9831/vx+984/pm38981210-246-11-3
    Average 90 stars, based on 1 article reviews
    co-crystal form of 48b vx-984 m9831 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    m9831  (MedChemExpress)
    93
    MedChemExpress m9831
    Synthesis of <t>VX-984:</t> A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.
    M9831, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vx+984+m9831/VX-984/pm37673883-426-4-7
    Average 93 stars, based on 1 article reviews
    m9831 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    m9831/vx-984  (AstraZeneca ltd)
    90
    AstraZeneca ltd m9831/vx-984
    Synthesis of <t>VX-984:</t> A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.
    M9831/Vx 984, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vx+984+m9831/m9831+vx+984/pm37580318-376-7-20
    Average 90 stars, based on 1 article reviews
    m9831/vx-984 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    m9831 vx 984  (MedChemExpress)
    93
    MedChemExpress m9831 vx 984
    Synthesis of <t>VX-984:</t> A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.
    M9831 Vx 984, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vx+984+m9831/VX-984/pm37580318-377-8-10
    Average 93 stars, based on 1 article reviews
    m9831 vx 984 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    vx-984 m9831  (Vertex Pharmaceuticals)
    90
    Vertex Pharmaceuticals vx-984 m9831
    Synthesis of <t>VX-984:</t> A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.
    Vx 984 M9831, supplied by Vertex Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vx+984+m9831/vx+984/pmc06157710-352-0-4
    Average 90 stars, based on 1 article reviews
    vx-984 m9831 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Synthesis of VX-984: A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.

    Journal: RSC Medicinal Chemistry

    Article Title: Targeting DNA-PK: medicinal chemistry insights into small-molecule inhibitor discovery and optimisation

    doi: 10.1039/d6md00119j

    Figure Lengend Snippet: Synthesis of VX-984: A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.

    Article Snippet: VX-984 (M9831) is a selective inhibitor of DNA-PK cs , developed by Vertex Pharmaceuticals.

    Techniques: Reflux